CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy

Ezgi Elmas; Ezgi Elmas; Noushin Saljoughian; Noushin Saljoughian; Marcelo de Souza Fernandes Pereira; Brian P. Tullius; Kinnari Sorathia; Robin J. Nakkula; Dean A. Lee; Dean A. Lee; Meisam Naeimi Kararoudi; Meisam Naeimi Kararoudi; Meisam Naeimi Kararoudi

doi:10.3389/fonc.2022.834002

Frontiers in Oncology (Apr 2022)

CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy

Ezgi Elmas,
Ezgi Elmas,
Noushin Saljoughian,
Noushin Saljoughian,
Marcelo de Souza Fernandes Pereira,
Brian P. Tullius,
Kinnari Sorathia,
Robin J. Nakkula,
Dean A. Lee,
Dean A. Lee,
Meisam Naeimi Kararoudi,
Meisam Naeimi Kararoudi,
Meisam Naeimi Kararoudi

Affiliations

Ezgi Elmas: Molecular, Cellular and Developmental Biology Graduate Program, The Ohio State University, Columbus, OH, United States
Ezgi Elmas: Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States
Noushin Saljoughian: Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States
Noushin Saljoughian: CRISPR/Gene Editing Core, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States
Marcelo de Souza Fernandes Pereira: Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States
Brian P. Tullius: Pediatric Cellular Therapy, AdventHealth for Children, Orlando, FL, United States
Kinnari Sorathia: Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States
Robin J. Nakkula: Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States
Dean A. Lee: Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States
Dean A. Lee: Department of Pediatrics, The Ohio State University, Columbus, OH, United States
Meisam Naeimi Kararoudi: Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States
Meisam Naeimi Kararoudi: CRISPR/Gene Editing Core, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States
Meisam Naeimi Kararoudi: Department of Pediatrics, The Ohio State University, Columbus, OH, United States

DOI: https://doi.org/10.3389/fonc.2022.834002
Journal volume & issue: Vol. 12

Abstract

Read online

Antitumor activity of immune cells such as T cells and NK cells has made them auspicious therapeutic regimens for adaptive cancer immunotherapy. Enhancing their cytotoxic effects against malignancies and overcoming their suppression in tumor microenvironment (TME) may improve their efficacy to treat cancers. Clustered, regularly interspaced short palindromic repeats (CRISPR) genome editing has become one of the most popular tools to enhance immune cell antitumor activity. In this review we highlight applications and practicability of CRISPR/Cas9 gene editing and engineering strategies for cancer immunotherapy. In addition, we have reviewed several approaches to study CRISPR off-target effects.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords